It is joint build by Lukang Pharma and the Center for Genetic Engineering and Biotechnology(CIGB).Through the introduction of vaccines, peptides, genetic engineering drugs and other advanced raw materials and preparations, Lukang Pharma and CIGB continuously expand the cooperation.

This provincial science and technology service platform, carrying the introduction of overseas advanced technologies, talents and teams; Actively carry out foreign technology transfer and allocate international innovation resources; Building a multilateral science and technology exchange platform and other main responsibilities. At present, it has carried out extensive cooperation with international scientific research institutions such as the United States, Cuba and South Korea.

Established by Lukang Pharma and Shandong University, it is a joint research institute integrating scientific innovation, technology research and development and pilot application. In-depth cooperation has been carried out in drug development and utilization of pharmaceutical derivatives. The research directions are genomics, microbial biochemistry, and microbial pharmacology.

It is jointly built by Lukang Pharma and Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, with the support of the government, which for industrialization and commercialization transformation  of biotechnology.

The total investment over 250 million yuan and cover an area of 20,000 square meters. There are four functional platforms: Strains screening and preservation, Metabolic control, Separation, purification and synthesis and Enzyme product development, which can complete the whole chain pilot scale up and production of synthetic biology products and new drug development.